Introduction: The isoniazid-resistant TB poses a threat to TB control efforts. Zimbabwe, one of the high TB burden countries, has not explored the burden of isoniazid resistant TB. Hence among all bacteriologically-confirmed TB patients diagnosed in Bulawayo City during March 2017 and December 2018, we aimed to assess the proportion with isoniazid resistant TB and associated factors. Also, we aimed to describe the TB treatment outcomes.
Methodology: A cohort study involving routinely collected data by the National TB Reference Laboratory (NTBRL) in Bulawayo City and National TB programme of Zimbabwe. The percentage with 95% confidence interval (CI) was used to express the proportion with isoniazid-resistant TB. The modified Poisson regression was used to assess the association of demographic and clinical characteristics with isoniazid mono-resistant TB.
Results: Of 2160 bacteriologically-confirmed TB patients, 1612 (74.6%) had their sputum received at the NTBRL and 743 (46.1%) had culture growth. Among those with culture growth, 34 (4.6%, 95% CI: 3.5-6.7) had isoniazid mono-resistant TB, 25 (3.3%, 95% CI: 2.2-4.9) had MDR-TB. Thus, 59 (7.9%, 95% CI: 6.1-10.1) had isoniazid-resistant TB. Children < 15 years had a higher prevalence of isoniazid mono-resistant TB (aPR= 3.93; 95% CI: 1.24-12.45). Among those with rifampicin sensitive TB, patients with isoniazid-sensitive TB had higher favourable treatment outcomes compared to those with isoniazid-resistant TB (86.3% versus 75.5%, p = 0.039).
Conclusions: The prevalence of isoniazid-resistant TB was low compared to neighbouring countries with high burden of TB-HIV. However, Zimbabwe should consider reviewing treatment guidelines for isoniazid mono-resistant TB due to the observed poor treatment outcomes.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8655986 | PMC |
| http://dx.doi.org/10.3855/jidc.12319 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Globally, drug-resistant tuberculosis (DR-TB) is responsible for 13% of mortality attributable to antimicrobial resistance. In Ethiopia, extrapulmonary tuberculosis (EPTB) is a significant public health challenge, and drug resistance (DR) in EPTB is often overlooked. In a cross-sectional study conducted between August 2022 and October 2023, we aimed to explore the magnitude of phenotypic drug resistance and identify genetic mutations linked to resistance using 189 Mycobacterium tuberculosis (MTB) isolates cultured from extrapulmonary clinical specimens.
View Article and Find Full Text PDFTreatment outcomes among patients with isoniazid mono-resistant tuberculosis in Mumbai, India: A retrospective cohort study.
J Clin Tuberc Other Mycobact Dis
December 2024
Médecins Sans Frontières, Southern Africa Medical Unit, Cape Town, South Africa.
Background: Tuberculosis (TB) remains a significant cause of mortality globally, with India accounting for 27% of the estimated number of people with TB. Multidrug-resistant TB (MDR-TB) and isoniazid (INH) resistance pose additional challenges to effective treatment. We aimed to describe treatment outcomes of INH mono-resistant TB patients under programmatic conditions in Mumbai, India.
View Article and Find Full Text PDFPrevalence of rifampicin and isoniazid mono-resistance among cases of pulmonary tuberculosis from Western Uttar Pradesh, North India.
Mol Biol Rep
October 2024
Department of Microbiology and Molecular Biology, ICMR-National JALMA Institute for Leprosy and Other Mycobacterial Diseases, Taj Ganj, Agra, 282 001, India.
Article Synopsis
- - The study investigates the prevalence of mono-resistance to rifampicin and isoniazid in tuberculosis (TB) patients in Western Uttar Pradesh, finding that 19.51% were multi-drug resistant while 8.54% and 6.10% were mono-resistant to rifampicin and isoniazid, respectively.
- - Out of 153 sputum samples processed, 54.24% tested positive for Mycobacterium tuberculosis, with the majority being identified through specific culture and testing methods.
- - Findings indicate a higher occurrence of mono-resistance in male patients over 45, those living in rural areas, experiencing weight loss, or with previous TB treatment; the study calls for better monitoring
Impact of isoniazid monoresistance on overall and vulnerable patient populations in Taiwan.
Emerg Microbes Infect
December 2024
Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
Article Synopsis
- *A study conducted in Taiwan from 2008 to 2017 analyzed the treatment outcomes of patients with both drug-susceptible and isoniazid mono-resistant TB, finding no significant delays in sputum culture conversion or increased mortality for those with mono-resistance compared to drug-susceptible patients.
- *However, younger, healthier patients without other health issues showed delayed culture conversion and worse outcomes, suggesting a need for early testing for isoniazid resistance in these groups to prevent potential disease spread.
Multi-drug resistant gene mutation analysis in by molecular techniques.
Iran J Microbiol
August 2024
Department of Microbiology, University of Dhaka, Dhaka-1000, Bangladesh.
Background And Objectives: Rifampicin (RIF) and isoniazid (INH), two most potent antibiotics, are prescribed to cure tuberculosis. , the causative agent of multidrug-resistant tuberculosis (MDR-TB), is resistant to these first-line drugs. Here, two molecular techniques were demonstrated such as PCR sequencing-based and GeneXpert assay for rapidly identifying MDR-TB.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!